Ancient DNA from horses slaughtered by Neanderthals sheds light on equine evolution
On Oct. 1, 2025, researchers excavating a site known as Schöningen in northern Germany reported finding 300,000-year-old genes,…
-
-
A rare form of leprosy existed in the Americas for thousands of years
On Jun. 30, 2025, a new study from an international team of researchers led by the Max Planck…
-
Pioneering cancer plasticity atlas will help predict response to cancer therapies
On Jun. 12, 2025, the Wellcome Sanger Institute, Parse Biosciences and the Computational Health Center at Helmholtz Munich…
-
Mechanism for treating muscle degeneration discovered
On Feb. 12, 2025, researchers at the Max Planck Institute released a study that could pave the way…
-
Oldest human DNA revealed family network that spanned Europe
On Dec. 12, 2024, a study led by scientists from the Max Planck Institute for Evolutionary Anthropology in…
-
Proteins that regulate animal stem cells are much older than animals themselves
On Nov. 15, 2024, an international research team including scientists from the Max Planck Institute reported that critical…
-
World-first cure for lethal skin disease achieved in landmark study
On Nov. 11, 2024, an international team of researchers has for the first time cured patients with Toxic…
-
Vaccine doses allocated to African countries hardest hit by mpox surge
On Nov. 6, 2024, the World Health Organization announced that the Access and Allocation Mechanism (AAM) for mpox…
-
Pfizer and BioNTech Received U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
On Aug. 22, 2024, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had approved…
-
National Academies reported COVID-19 vaccines don’t cause many potential harms
On Apr. 16, 2024, the National Academies of Sciences, Engineering, and Medicine reported that the COVID-19 vaccines made…
-
BioNTech aimed to start mRNA vaccine output in Rwanda in 2025
On Dec. 18, 2023, COVID-19 vaccine maker BioNTech (22UAy.DE) announced that it aims to start production at its…
-
BioNTech and Australiaﾒs State of Victoria signed agreement on strategic partnership to strengthen mRNA rcosystem
On Dec. 7, 2023, BioNTech announced that it had signed a multi-year strategic partnership with the State of…
-
Researchers document third known case of HIV remission involving stem cell transplant
On Feb. 15, 2023, it was reported that a 53-year-old man in Germany had become at least the…
-
BioNTech announced strategic partnership with UK Government to provide up to 10,000 patients with personalized mRNA cancer immunotherapies
On Jan. 5, 2023, BioNTech announced that the Company had signed a Memorandum of Understanding with the Government…
-
BioNTech and Fosun Pharma announced regulatory approval of mono- and bivalent COVID-19 vaccine COMIRNATYﾮ in individuals 12 years and older in Hong Kong
On Dec. 23, 2022, BioNTech and Fosun Pharmaceutical announced that they had received the certificates of registration as…
-
German Health Authority expanded recommendation for use of Novavax COVID-19 vaccine as a booster
On Dec. 16, 2022, Novavax announced that the Standing Committee on Vaccination (STIKO) in Germany had expanded its…
-
Biotechnology | COVID-19 | FDA | Influenza | Vaccine
Pfizer and BioNTech received U.S. FDA Fast Track Designation for single-dose mRNA-based vaccine candidate against COVID-19 and influenza
On Dec. 9, 2022, Pfizer and BioNTech announced the companies had received Fast Track Designation from the U.S….
-
Biotechnology | COVID-19 | FDA | Vaccine
Pfizer and BioNTech received U.S. FDA EUA for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children
On Dec. 8, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration had granted Emergency Use…
-
Pfizer and BioNTech advancd next-generation COVID-19 vaccine
On Nov. 16, 2022, Pfizer and BioNTech announced that the companies had initiated a Phase 1 study to…
-
Pfizer and BioNTech announced updated data for Omicron BA.4/BA.5-adapted bivalent booster
On Nov. 4, 2022, Pfizer and BioNTech announced updated data from a Phase 2/3 clinical trial demonstrating a…
-
U.S. FDA recommended Novavax COVID-19 vaccine, adjuvanted as a booster in adults
On Oct. 19, 2022, the U.S. Food and Drug Administration (FDA) recommended the use of the Novavax COVID-19…
-
Biotechnology | Diagnostics | Infectious Disease | Polio | Vaccine | WHO
Global leaders committed US$ 2.6 billion at World Health Summit to end polio
On Oct. 18, 2022, global leaders confirmed US$ 2.6 billion in funding toward the Global Polio Eradication Initiative’s…
-
Pfizer and BioNTech announced positive early data from clinical trial of Omicron BA.4/BA.5-adapted bivalent booster
On Oct. 13, 2022, Pfizer and BioNTech announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating…
-
Biotechnology | CDC | COVID-19 | FDA
Pfizer and BioNTech received U.S. FDA EUA for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in children
On Oct. 12, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration granted Emergency Use…
-
Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5-adapted bivalent vaccinebBooster in children 5 through 11 years of age
On Sept. 28, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
-
Biotechnology | COVID-19 | FDA
Pfizer and BioNTech submitted application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent vaccine booster in children 5 through 11 years of age
On Sept. 28, 2022, Pfizer and BioNTech announced they have completed a submission to the U.S. Food and…
-
Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5 adapted bivalent vaccine
On Aug. 26, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
-
Pfizer and BioNTech announced updated COVID-19 vaccine data supporting efficacy in children 6 months through 4 years of age
On Aug. 23, 2022, Pfizer and BioNTech announced updated efficacy results from a Phase 2/3 trial evaluating a…
-
Pfizer and BioNTech announced clinical trial of next-generation vaccine candidate based on enhanced spike protein design
On Jul. 27, 2022, Pfizer and BioNTech announced that the companies had initiated a randomized, active-controlled, observer-blind, Phase…
-
Pfizer and BioNTech submitted a variation to EMA for vaccination of children ages 6 months to less than 5 Years with COMIRNATY
On Jul. 8, 2022, Pfizer and BioNTech announced that the companies had submitted a variation to the European…
